Patents Assigned to Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
  • Patent number: 10931961
    Abstract: A method for encoding high dynamic range (HDR) images involves providing a lower dynamic range (LDR) image, generating a prediction function for estimating the values for pixels in the HDR image based on the values of corresponding pixels in the LDR image, and obtaining a residual frame based on differences between the pixel values of the HDR image and estimated pixel values. The LDR image, prediction function and residual frame can all be encoded in data from which either the LDR image of HDR image can be recreated.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: February 23, 2021
    Assignee: Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.
    Inventors: Alexander Efremov, Rafal Mantiuk, Grzegorz Krawczyk, Karol Myszkowski, Hans-Peter Seidel
  • Patent number: 10913710
    Abstract: The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said substituted benzene disulfonamides are binding to the prenyl binding pocket of PDE6? and therefore, are useful for the prophylaxis and treatment of cancer by inhibition of the binding of PDE6? to farnesylated Ras proteins and thereby, inhibition of oncogenic Ras signaling in cells.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: February 9, 2021
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V
    Inventors: Herbert Waldmann, Pablo Antonio Martin-Gago, Sandip Murarka, Christian Klein, Philippe Bastiaens, Alfred Wittinghofer, Eyad Kalawy Fansa
  • Publication number: 20210008207
    Abstract: The present invention relates to inhibitors of the interaction between H. pylori IIopQ and a member of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family as well as to immunogenic compositions based on H. pylori HopQ. The present invention further relates to the use of the inhibitors and immunogenic compositions for preventing or treating a disease or disorder caused by or associated with H. pylori.
    Type: Application
    Filed: July 20, 2017
    Publication date: January 14, 2021
    Applicants: TECHNISCHE UNIVERSITÄT MÜNCHEN, MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Anahita JAVAHERI, Tobias KRUSE, Markus GERHARD, Bernhard B. SINGER, Daniel HORNBURG, Han REMAUT, Matthias MANN, Felix MEISSNER, Steffen BACKERT
  • Patent number: 10884397
    Abstract: A method for devising an optimum control policy of a controller for controlling a system includes optimizing at least one parameter that characterizes the control policy. A Gaussian process model is used to model expected dynamics of the system. The optimization optimizes a cost function which depends on the control policy and the Gaussian process model with respect to the at least one parameter. The optimization is carried out by evaluating at least one gradient of the cost function with respect to the at least one parameter. For an evaluation of the cost function a temporal evolution of a state of the system is computed using the control policy and the Gaussian process model. The cost function depends on an evaluation of an expectation value of a cost function under a probability density of an augmented state at time steps.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: January 5, 2021
    Assignees: Robert Bosch GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Andreas Doerr, Sebastian Trimpe, Duy Nguyen-Tuong
  • Patent number: 10883137
    Abstract: The present invention relates to methods for detection of nucleotide polymerase activity and methods of detecting compounds that modulate nucleotide polymerase activity, by detecting product formation of the nucleotide polymerase to be tested based on determination of close proximity of two labeled nucleotide probes able to bind the product of the nucleotide polymerase. It is preferred that proximity dependent energy transfer, such as forster resonance energy transfer, between said labeled nucleotide probes is determined. The invention further provides kits comprising components for carrying out the inventive methods for detection of nucleotide polymerase activity.
    Type: Grant
    Filed: May 30, 2016
    Date of Patent: January 5, 2021
    Assignees: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., LEAD DISCOVERY CENTER GMBH
    Inventors: Tim Bergbrede, Nils-Göran Larsson, Claes Gustafsson, Maria Falkenberg-Gustafsson
  • Publication number: 20200410944
    Abstract: The invention relates to a system for displaying information to a user, comprising: an emission device (12, 13) arranged to emit light so as to display information to a user (18), the emission device (12, 13) being adapted to emit the light in a pulsed manner so that the intensity of the light varies between a high value and a low value, a selective viewing device (16) comprising a panel, the panel being adapted so that the user can view the light (11?) which is emitted by the emission device through that panel so as to visually perceive the information being displayed, the panel having a variable transparency which can be varied between a state of high transparency and a state of low transparency, the system being adapted to synchronize the emission device (12, 13) and the selective viewing device (16) so that the states of the emission device emitting light at a high-intensity value and the states of the panel of the selective viewing device of high transparency overlap in time, the emission device being ad
    Type: Application
    Filed: March 9, 2018
    Publication date: December 31, 2020
    Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Ivan C. Baines, Moritz Kreysing
  • Patent number: 10864261
    Abstract: The present invention relates to a synthetic saccharide of general formula (I) that is related to Streptococcus pneumoniae serotype 2 capsular polysaccharide, a conjugate thereof and the use of said saccharide and conjugate for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae type 2 bacteria.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: December 15, 2020
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Naeem Khan, Madhu Emmadi
  • Publication number: 20200362312
    Abstract: The invention relates to a method of culturing an epithelial cell on a solid surface.
    Type: Application
    Filed: January 18, 2019
    Publication date: November 19, 2020
    Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Francesco BOCCELLATO, Thomas F. MEYER
  • Patent number: 10837062
    Abstract: A method of treating a human patient with depressive and/or anxiety symptoms which includes administering an effective amount of a V1B receptor antagonist and/or CRHR1 antagonist to the patient in need thereof, wherein the patient's genome has certain polymorphoric variants.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: November 17, 2020
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Florian Holsboer, Bertram Müller-Myhsok
  • Patent number: 10829515
    Abstract: The present invention relates in a first aspect to a method for the purification of biological macromolecular complexes. Typically, no chromatography steps are applied. That is, the present invention relates to a method for the purification of biological macromolecular complexes Furthermore, the present invention relates to a method for crystallization of biological macromolecular complexes comprising the step of purification as described followed by crystallization in a reservoir solution containing a water-soluble polymer. Furthermore, purified biological macromolecular complexes obtainable by the method according to the present invention are provided as well as crystallized biological macromolecular complexes. Finally, a method for determining the suitability of a candidate compound for inhibiting the 20S proteasome of an individual is provided.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: November 10, 2020
    Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Ashwin Chari, Holger Stark, Jil Schrader, Fabian Henneberg
  • Patent number: 10828358
    Abstract: The present invention relates to immunogenic compositions and their use in the prevention or treatment of diseases or disorders caused by or associated with Helicobacter pylori, in particular H. pylori infection and gastroduodenal disorders caused by H. pylori. The present invention further relates to methods of detecting H. pylori infection in a subject.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: November 10, 2020
    Assignees: TECHNISCHE UNIVERSITÄT MÜNCHEN, MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Tobias Kruse, Daniel Hornburg, Markus Gerhard, Matthias Mann, Felix Meissner
  • Patent number: 10822401
    Abstract: The marginal zone (MZ) and B1 subsets of B cells, which differ from conventional follicular (FO) B cells both developmentally and functionally, are involved in early responses to infectious pathogens and the production of self-reactive antibodies. A novel gene, mzb1, is expressed at high levels in MZ and B1 B cells but at low level, if at all, in FO B cells. MZB1 is involved in the regulation of proliferation, BCR-mediated signal transduction, and antibody production in B cells. Inhibitors, activators and enhancers of MZB1 expression or activity can be used as immune modulators for research and therapeutic purposes.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: November 3, 2020
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Rudolf Grosschedl, Henrik Flach, Sola Kim, Marlena Duchniewicz, Bernadette Schreiner, Marc Rosenbaum
  • Publication number: 20200339668
    Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.
    Type: Application
    Filed: July 6, 2020
    Publication date: October 29, 2020
    Applicants: X4 Pharmaceuticals (Austria) GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.
    Inventors: Valeria SZIJÁRTO, Gábor NAGY, Luis GUACHALLA, Katharina RAMONI, Adriana BADARAU, Eszter NAGY, Tim ROLLENSKE, Hedda WARDEMANN, Irina MIRKINA
  • Patent number: 10794908
    Abstract: The present invention discloses functionalized nanomembranes, a method for preparation and their use. The functionalized nanomembrane comprises a) a first layer comprising a nanomaterial, b) a second layer comprising a biorepulsive material, the second layer being attached to at least one side of the first layer, and c) affinity groups, attached to the second layer.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: October 6, 2020
    Assignees: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Quantifoil Micro Tools GmbH
    Inventors: Andreas Terfort, Daniel Rhinow, Andrey Turchanin
  • Publication number: 20200280159
    Abstract: A broadband light source device for creating broadband light pulses includes a hollow-core fiber and a pump laser source device. The hollow-core fiber is configured to create the broadband light pulses by an optical non-linear broadening of pump laser pulses. The hollow-core fiber includes a filling gas, an axial hollow light guiding fiber core configured to support core modes of a guided light field, and an inner fiber structure surrounding the fiber core and configured to support transverse wall modes of the guided light field. The pump laser source device is configured to create and provide the pump laser pulses at an input side of the hollow-core fiber. The transverse wall modes include a fundamental transverse wall mode and second and higher order transverse wall modes.
    Type: Application
    Filed: May 15, 2020
    Publication date: September 3, 2020
    Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Patrick Sebastian UEBEL, Philip St. J. RUSSELL, Sebastian Thomas BAUERSCHMIDT
  • Patent number: 10759848
    Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: September 1, 2020
    Assignees: ARSANIS Biosciences GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.
    Inventors: Valeria Szijárto, Gábor Nagy, Luis Guachalla, Katharina Ramoni, Adriana Badarau, Eszter Nagy, Tim Rollenske, Hedda Wardemann, Irina Mirkina
  • Patent number: 10755464
    Abstract: Present application refers to a method, a model generation unit and a computer program (product) for generating trained models (M) of moving persons, based on physically measured person scan data (S). The approach is based on a common template (T) for the respective person and on the measured person scan data (S) in different shapes and different poses. Scan data are measured with a 3D laser scanner. A generic personal model is used for co-registering a set of person scan data (S) aligning the template (T) to the set of person scans (S) while simultaneously training the generic personal model to become a trained person model (M) by constraining the generic person model to be scan-specific, person-specific and pose-specific and providing the trained model (M), based on the co-registering of the measured object scan data (S).
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: August 25, 2020
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Michael Black, David L. Hirshberg, Matthew Loper, Eric Rachlin, Alex Weiss
  • Patent number: 10739334
    Abstract: A capsule suitable for oxygen and temperature sensing contains: i) at least one first sensitizer compound being capable of energy transfer to triplet oxygen, ii) at least one compound being capable of reacting with and inactivating singlet oxygen, iii) at least one second sensitizer compound being capable of absorbing radiation at a second frequency v2 and of emitting light at a fourth frequency v4, iv) at least one emitter compound, wherein the at least one second sensitizer compound is capable of transferring energy to the at least one emitter compound and wherein the at least one emitter compound, after obtaining energy transferred from the at least one second sensitizer compound, is capable of emitting light at a third frequency v3, wherein the following equation is fulfilled: v3>v2, wherein the upper energy limit of the first triplet energy band of the first sensitizer compound is lower than the lower energy limit of the second triplet energy band of the second sensitizer compound and lower than the
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: August 11, 2020
    Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Katharina Landfester, Yury Avlasevich, Dzmitry Busko, Frederik Wurm, Stanislav Balouchev
  • Patent number: 10711244
    Abstract: The present invention relates to a method for producing mammalian neural plate border stem cells (NPBSCs), comprising: (a) differentiation of mammalian pluripotent stem cells by (a-i) culturing mammalian pluripotent stem cells in pluripotent stem cell medium for about 24 to about 96 hours, wherein the pluripotent stem cell medium comprises: (i) an inhibitor of the activin/TGF-? signalling pathway; (ii) an inhibitor of the BMP signalling pathway; (iii) an activator of the canonical WNT signalling pathway; and (iv) an activator of the Hedgehog signalling pathway; subsequently (a-ii) culturing the cells obtained in step (a-i) for about 24 to about 96 hours in a neural medium, wherein the neural medium comprises: (i) an inhibitor of the Activin/TGF-? signalling pathway; (ii) an inhibitor of the BMP signalling pathway; (iii) an activator of the canonical WNT signalling pathway; and (iv) an activator of the Hedgehog signalling pathway; subsequently (a-iii) culturing the cells obtained in step (a-ii) for about 24 to
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: July 14, 2020
    Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Hans R. Schoeler, Jared L. Sterneckert, Michael Glatza, Peter Reinhardt
  • Patent number: 10703735
    Abstract: The invention provides novel 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: July 7, 2020
    Assignees: Lead Discovery Center GmbH, Max Planck Gesellschaft zur Förderung der Wissenschaften e. V.
    Inventors: Raffaella Di Lucrezia, Tim Bergbrede, Peter Nussbaumer, Uwe Koch, Bert Klebl, Axel Choidas, Anke Unger, Nils-Göran Larsson, Maria Falkenberg-Gustafsson, Claes M. Gustafsson